DCF — ASPIRUS RIVERVIEW HOSPITAL & CLINICS
Enterprise Value: $188.3M
🛡️ Public data only — no PHI permitted on this instance.
← DashboardPRFProfileMEMIC MemoBRGBridgeCIComp IntelSCNScenariosAIMLDCFDCFLBOLBOFIN3-StmtMKTMarketDENDenialRETReturnsLVRLeversWFLWaterfallPLYPlaybookTRDTrendsPREDPredictedMEM2Memo
$188.3M
Enterprise Value
$51.4M
PV of Cash Flows
$136.9M
PV of Terminal Value
$220.5M
Terminal Value
10.0%
WACC
2.5%
Terminal Growth
Cash Flow Projections
PROJ| Year | Revenue | EBITDA | Margin | FCF | PV(FCF) |
|---|---|---|---|---|---|
| Year 1 | $166.1M | $22.5M | 14.0% | $10.9M | $9.9M |
| Year 2 | $171.1M | $24.9M | 15.0% | $12.5M | $10.3M |
| Year 3 | $176.2M | $27.4M | 16.0% | $14.2M | $10.7M |
| Year 4 | $181.5M | $29.2M | 16.0% | $15.3M | $10.5M |
| Year 5 | $186.9M | $30.5M | 16.0% | $16.1M | $10.0M |
Interpretation
INTAt a WACC of 10.0% and terminal growth of 2.5%, enterprise value is $188.3M. Terminal value accounts for 73% of total EV — typical range (60-80%).
Next steps: Check the LBO model to see equity returns at this entry price, or the EBITDA bridge to model value creation levers.
Assumptions
ASSMrevenue base$161.3M
revenue growth rates[0.03, 0.03, 0.03, 0.03, 0.03]
ebitda margin base0.13067611972680862
ebitda margin improvement bps[50, 100, 100, 50, 25]
capex pct revenue0.04
nwc pct revenue0.08
tax rate0.25
projection years5